美国第二家生物医药公司开始进行有关新冠疫苗的安全测试。

A second US company is poised¹ to begin safety test of a vaccine² against COVID-19 on Monday.

 

The Phase 1 study will enroll³ up to 40 healthy adult volunteers in Philadelphia and Kansas City, where screening of potential participants has already begun, said the company.

 

The first dosing is planned for Monday. Each participant will receive two doses of INO-4800 four weeks apart, and the initial immune responses and safety data from the study are expected by late summer.

 

Additional preclinical trials, including challenge studies, will continue in parallel with the Phase 1 clinical trial, according to the company.

 

The study is a first step to see if the vaccine appears safe enough for larger tests needed to prove whether it will protect. Even if the research goes well, it is expected to take over a year before any vaccine could be widely available.

 

The first safety test in people of a different vaccine candidate, developed by the US National Institutes of Health and Moderna Inc., began in Seattle last month.

 

 

点击收听单词发音